Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
04 nov. 2024 16h30 HE
|
Interpace Biosciences, Inc.
●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase...
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
01 août 2024 16h30 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ●Q2...
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
09 mai 2024 16h01 HE
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc....
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
27 mars 2023 16h05 HE
|
Interpace Biosciences, Inc.
●Q4 Revenue of $8.3 million ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
31 août 2022 17h30 HE
|
Interpace Biosciences, Inc.
Interpace Transitions to focused Molecular Diagnostics BusinessDisposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 ...
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
11 mai 2022 08h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in...
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering
12 janv. 2022 16h41 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully...
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
03 janv. 2022 17h07 HE
|
Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
11 mai 2021 16h47 HE
|
Interpace Biosciences, Inc.
● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business ● Q2 Revenue Expected to Exceed $11 million ● On Track to Exceed Full Year 2021...
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
03 mai 2021 08h00 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...